CAR-T细胞治疗在儿童中的毒副作用

doi:10.12372/jcp.2024.22e1605

Abstract

Abstract:

Chimeric antigen receptor (CAR)-T cells have become one of the most promising methods for the treatment of malignant tumors due to their specific recognition function and cytotoxicity. However, it also has a series of side effects, especially in children. Toxic reactions can develop rapidly and endanger life in severe cases. In this paper, the side effects of CAR-T cell therapy in children, as well as its clinical manifestations and treatment are summarized, aiming to optimize its application in children.

Key words: chimeric antigen receptor T cell, side effect, child

YIN Mengmeng, HU Qun. Side effects of CAR-T cell therapy in children[J].Journal of Clinical Pediatrics, 2024, 42(4): 361-366.

References 46

[1]	Abramson JS, Lunning M, Palomba ML. Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 446-453. doi: 10.1200/EDBK_238693 pmid: 31099671
[2]	Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy[J]. Ann Oncol, 2021, 32(1): 34-48. doi: 10.1016/j.annonc.2020.10.478 pmid: 33098993
[3]	Brown A, Gutierrez C. Comments regarding "ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells"[J]. Biol Blood Marrow Transplant, 2019, 25(6): e209-e210. doi: 10.1016/j.bbmt.2019.02.027
[4]	Frey N, Porter D. Cytokine Release Syndrome with chimeric antigen receptor T cell therapy[J]. Biol Blood Marrow Transplant, 2019, 25(4): e123-e127. doi: 10.1016/j.bbmt.2018.12.756
[5]	Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)[J]. Haematologica, 2020, 105(2): 297-316. doi: 10.3324/haematol.2019.229781 pmid: 31753925
[6]	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148 pmid: 28925994
[7]	Nair R, Westin J. CAR T-cells[J]. Adv Exp Med Biol, 2020, 1244: 215-233. doi: 10.1007/978-3-030-41008-7_10 pmid: 32301017
[8]	Chavez JC, Jain MD, Kharfan-Dabaja MA. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models[J]. Hematol Oncol Stem Cell Ther, 2020, 13(1): 1-6. doi: S1658-3876(19)30050-0 pmid: 31202671
[9]	Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma[J]. Blood Adv, 2020, 4(13): 3123-3127. doi: 10.1182/bloodadvances.2020002328 pmid: 32645136
[10]	Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia[J]. J Immunother Cancer, 2021, 9(8): e002287. doi: 10.1136/jitc-2020-002287
[11]	Torre M, Solomon IH, Sutherland CL, et al. Neuro-pathology of a case with fatal CAR T-cell-associated cerebral edema[J]. J Neuropathol Exp Neurol, 2018, 77(10): 877-882. doi: 10.1093/jnen/nly064
[12]	Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions[J]. J Natl Cancer Inst, 2019, 111(7): 646-654. doi: 10.1093/jnci/djz017 pmid: 30753567
[13]	Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J]. Cancer Discov, 2017, 7(12): 1404-1419. doi: 10.1158/2159-8290.CD-17-0698 pmid: 29025771
[14]	Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia[J]. Cancer Discov, 2018, 8(8): 958-971. doi: 10.1158/2159-8290.CD-17-1319 pmid: 29880584
[15]	Traube C, Silver G, Kearney J, et al. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU*[J]. Crit Care Med, 2014, 42(3): 656-663. doi: 10.1097/CCM.0b013e3182a66b76 pmid: 24145848
[16]	Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells[J]. Blood, 2019, 133(20): 2212-2221. doi: 10.1182/blood-2018-12-893396 pmid: 30808634
[17]	Zhou J, Zhang Y, Shan M, et al. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma[J]. Front Immunol, 2022, 13: 997589. doi: 10.3389/fimmu.2022.997589
[18]	Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma[J]. Haematologica, 2021, 106(4): 978-986. doi: 10.3324/haematol.2019.238634 pmid: 32327504
[19]	Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells[J]. Bone Marrow Transplant, 2019, 54(10): 1643-1650. doi: 10.1038/s41409-019-0487-3
[20]	Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies[J]. Blood Adv, 2020, 4(15): 3776-3787. doi: 10.1182/bloodadvances.2020002509 pmid: 32780846
[21]	Schubert ML, Dietrich S, Stilgenbauer S, et al. Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(9): 1575-1580. doi: 10.1016/j.bbmt.2020.04.025
[22]	Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy[J]. Pediatr Blood Cancer, 2018, 65(4): 10.1002/pbc.26914.
[23]	Mahmoudjafari Z, Hawks KG, Hsieh AA, et al. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States[J]. Biol Blood Marrow Transplant, 2019, 25(1): 26-33. doi: 10.1016/j.bbmt.2018.09.024
[24]	Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131(1): 121-130. doi: 10.1182/blood-2017-07-793760 pmid: 29038338
[25]	Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper[J]. Infection, 2021, 49(2): 215-231. doi: 10.1007/s15010-020-01521-5
[26]	Strati P, Nastoupil LJ, Fayad LE, et al. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection[J]. Blood, 2019, 133(26): 2800-2802. doi: 10.1182/blood.2019000888 pmid: 31101626
[27]	Hwang JP, Torres HA. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients[J]. Curr Opin Infect Dis, 2018, 31(6): 535-541. doi: 10.1097/QCO.0000000000000500 pmid: 30299355
[28]	Hill J A, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies[J]. Blood, 2020, 136(8): 925-935. doi: 10.1182/blood.2019004000 pmid: 32582924
[29]	Dai CY, Chuang WL, Yu ML. EASL recommendations on treatment of hepatitis C: Final update of the series-Some issues[J]. J Hepatol, 2021, 74(2): 473-474. doi: 10.1016/j.jhep.2020.10.013
[30]	Hiwarkar P, Kosulin K, Cesaro S, et al. Management of adenovirus infection in patients after haematopoietic stem cell transplantation: State-of-the-art and real-life current approach: a position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation[J]. Rev Med Virol, 2018, 28(3): e1980.
[31]	Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(2): 369-381. doi: 10.1016/j.bbmt.2018.09.038
[32]	Vena A, Bouza E, Alvarez-Uria A, et al. The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin[J]. Clin Microbiol Infect, 2017, 23(12): 1000-1001.
[33]	Howard SC, Trifilio S, Gregory TK, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review[J]. Ann Hematol, 2016, 95(4): 563-573. doi: 10.1007/s00277-015-2585-7 pmid: 26758269
[34]	Guha A, Addison D, Jain P, et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis[J]. Biol Blood Marrow Transplant, 2020, 26(12): 2211-2216. doi: 10.1016/j.bbmt.2020.08.036
[35]	Burstein DS, Maude S, Grupp S, et al. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience[J]. Biol Blood Marrow Transplant, 2018, 24(8): 1590-1595. doi: 10.1016/j.bbmt.2018.05.014
[36]	Denton CC, Gange WS, Abdel-Azim H, et al. Bilateral retinal detachment after chimeric antigen receptor T-cell therapy[J]. Blood Adv, 2020, 4(10): 2158-2162. doi: 10.1182/bloodadvances.2020001450 pmid: 32428218
[37]	Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-Cell (CAR-T) therapy for diffuse large B-cell lymphoma[J]. Am J Kidney Dis, 2020, 76(1): 63-71. doi: S0272-6386(19)31125-4 pmid: 31973908
[38]	Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial[J]. J Clin Oncol, 2020, 38(17): 1938-1950. doi: 10.1200/JCO.19.03279 pmid: 32286905
[39]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. doi: 10.1016/j.bbmt.2018.12.758
[40]	Hashmi H, Bachmeier C, Chavez JC, et al. Haemo-phagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy[J]. Br J Haematol, 2019, 187(2): e35-e38.
[41]	Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis[J]. Blood, 2020, 135(16): 1332-1343. doi: 10.1182/blood.2019000936 pmid: 32107531
[42]	Cruz CR, Hanley PJ, Liu H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience[J]. Cytotherapy, 2010, 12(6): 743-749. doi: 10.3109/14653241003709686 pmid: 20429793
[43]	Shah NN, Qin H, Yates B, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy[J]. Blood Adv, 2019, 3(15): 2317-2322. doi: 10.1182/bloodadvances.2019000219 pmid: 31387880
[44]	Wolfl M, Rasche M, Eyrich M, et al. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL[J]. Blood Adv, 2018, 2(12): 1382-1385. doi: 10.1182/bloodadvances.2018018093
[45]	Good ML, Malekzadeh P, Kriley IR, et al. Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report[J]. Pediatr Transplant, 2020, 24(2): e13653. doi: 10.1111/petr.v24.2
[46]	Steineck A, Wiener L, Mack JW, et al. Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy[J]. Pediatr Blood Cancer, 2020, 67(5): e28249. doi: 10.1002/pbc.v67.5

Side effects of CAR-T cell therapy in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 46

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28.
[2]	LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34.
[3]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[4]	JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13.
[5]	QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752.
[6]	FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773.
[7]	JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790.
[8]	ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804.
[9]	CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816.
[10]	DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672.
[11]	LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677.
[12]	HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683.
[13]	WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690.
[14]	MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703.
[15]	WANG Ye, ZHANG Linlin, CHI Zuofei, SUN Ruowen, JIANG Zehui, XU Gang. A case of clinical report of T-lymphoblastic lymphoma secondary to acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 722-727.